{"id":3841,"date":"2019-01-16T12:00:31","date_gmt":"2019-01-16T11:00:31","guid":{"rendered":"https:\/\/www.nanexa.com\/mfn_news\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\/"},"modified":"2020-06-26T14:11:26","modified_gmt":"2020-06-26T12:11:26","slug":"nya-prekliniska-resultat-optimala-for-nex-18-projektet","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\/","title":{"rendered":"Nya prekliniska resultat optimala f\u00f6r NEX-18 projektet"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><span><strong><\/strong><\/span><\/p>\n<\/div>\n<p><span>Nanexa har i dagarna erh\u00e5llit resultat fr\u00e5n en preklinisk farmakokinetisk studie (en s\u00e5 kallad PK-studie) i r\u00e5tta med sitt drug delivery-system PharmaShell\u00ae. Denna g\u00e5ng har PharmaShell-skalen designats f\u00f6r att ge en kortare fris\u00e4ttning, p\u00e5 runt en vecka, och samtidigt eliminera den initiala fris\u00e4ttningen\u00a0(den s\u00e5 kallade \u201dbursten\u201d)\u00a0f\u00f6r att slippa en initial fris\u00e4ttningstopp av l\u00e4kemedlet.<\/span><\/p>\n<p><span>Resultaten fr\u00e5n studien visar tydligt att den nya designen av PharmaShell\u00ae ger en optimal grund f\u00f6r NEX-18 projektet* d\u00e4r just en s\u00e5dan fris\u00e4ttningsprofil efterstr\u00e4vas.<\/span><\/p>\n<p><span>Nanexas VD David Westberg kommenterar:<\/span><\/p>\n<p><span>Vi har redan tidigare visat att vi kan skapa en formulering med begr\u00e4nsad initial fris\u00e4ttning. Att vi nu lyckats eliminera denna koncentrationstopp helt anser vi i Bolaget \u00e4r helt unikt. Vi kan genom detta framsteg avsev\u00e4rt begr\u00e4nsa biverkningar som beror p\u00e5 alltf\u00f6r h\u00f6ga koncentrationer av l\u00e4kemedel i blodet. Att vi samtidigt lyckats skapa en en-veckas dep\u00e5beredning visar p\u00e5 styrkan och flexibiliteten i PharmaShell\u00ae-plattformen. Vi har nu resultat som st\u00f6djer b\u00e5de korta och l\u00e5nga dep\u00e5beredningar, vilket \u00f6ppnar f\u00f6r flera anv\u00e4ndningsomr\u00e5den.<\/span><\/p>\n<p><span>*NEX-18 projektet \u00e4r det produktprojekt som Nanexa driver f\u00f6r att f\u00f6rb\u00e4ttra behandlingen inom leukemiindikationerna MDS\/ AML.<\/span><\/p>\n<p><span>F\u00f6r mer information kontakta:<br \/>David Westberg\u00a0\u2013\u00a0VD, Nanexa AB (publ)\u00a0Telefon: 0709 &#8211; 42 83 03<br \/>E-post: david.westberg@nanexa.se www.nanexa.com<\/span><\/p>\n<p><span>Om Nanexa AB (publ)<\/span><\/p>\n<p><span>Nanexa AB \u00e4r ett nanoteknologiskt drug delivery-f\u00f6retag som fokuserar verksamheten p\u00e5 utvecklingen av PharmaShell\u00ae\u00a0som \u00e4r ett nytt och banbrytande drug delivery-system som bed\u00f6ms ha en stor potential inom ett flertal indikationsomr\u00e5den. Inom ramen f\u00f6r PharmaShell\u00ae\u00a0har Nanexa samarbetsavtal med bland andra AstraZeneca.<\/span><\/p>\n<p><\/p>\n<p><span><strong><\/strong><\/span><\/p>\n<p><\/p>\n<p><span><strong><\/strong><\/span><\/p>\n<div class=\"mfn-footer mfn-attachment\">\n<p><strong>Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a href=\"https:\/\/mb.cision.com\/Main\/12591\/2719594\/977624.pdf\" target=\"_blank\" rel=\"nofollow noopener noreferrer\">Read as PDF<\/a><\/p>\n<\/div>\n<div class=\"mfn-footer\"><\/div>\n","protected":false},"excerpt":{"rendered":"<\/p>\n<p>Nanexa har i dagarna erh\u00e5llit resultat fr\u00e5n en preklinisk farmakokinetisk studie (en s\u00e5 kallad PK-studie) i r\u00e5tta med sitt drug delivery-system PharmaShell\u00ae. Denna g\u00e5ng har PharmaShell-skalen designats f\u00f6r att ge en kortare fris\u00e4ttning,<\/p>\n<p><a class=\"read-more\" href=\"https:\/\/nanexa.com\/sv\/mfn_news\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\/\">L\u00e4s mer<\/a><\/p>\n","protected":false},"template":"","class_list":["post-3841","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nya prekliniska resultat optimala f\u00f6r NEX-18 projektet - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nya prekliniska resultat optimala f\u00f6r NEX-18 projektet - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa har i dagarna erh\u00e5llit resultat fr\u00e5n en preklinisk farmakokinetisk studie (en s\u00e5 kallad PK-studie) i r\u00e5tta med sitt drug delivery-system PharmaShell\u00ae. Denna g\u00e5ng har PharmaShell-skalen designats f\u00f6r att ge en kortare fris\u00e4ttning,L\u00e4s mer\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta property=\"article:modified_time\" content=\"2020-06-26T12:11:26+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minut\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\\\/\",\"name\":\"Nya prekliniska resultat optimala f\u00f6r NEX-18 projektet - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2019-01-16T11:00:31+00:00\",\"dateModified\":\"2020-06-26T12:11:26+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nya prekliniska resultat optimala f\u00f6r NEX-18 projektet\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nya prekliniska resultat optimala f\u00f6r NEX-18 projektet - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\/","og_locale":"sv_SE","og_type":"article","og_title":"Nya prekliniska resultat optimala f\u00f6r NEX-18 projektet - Nanexa AB","og_description":"Nanexa har i dagarna erh\u00e5llit resultat fr\u00e5n en preklinisk farmakokinetisk studie (en s\u00e5 kallad PK-studie) i r\u00e5tta med sitt drug delivery-system PharmaShell\u00ae. Denna g\u00e5ng har PharmaShell-skalen designats f\u00f6r att ge en kortare fris\u00e4ttning,L\u00e4s mer","og_url":"https:\/\/nanexa.com\/mfn_news\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\/","og_site_name":"Nanexa AB","article_modified_time":"2020-06-26T12:11:26+00:00","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"1 minut"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\/","url":"https:\/\/nanexa.com\/mfn_news\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\/","name":"Nya prekliniska resultat optimala f\u00f6r NEX-18 projektet - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2019-01-16T11:00:31+00:00","dateModified":"2020-06-26T12:11:26+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nya-prekliniska-resultat-optimala-for-nex-18-projektet\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nya prekliniska resultat optimala f\u00f6r NEX-18 projektet"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/3841","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=3841"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}